Polymyositis is a chronic idiopathic inflammatory myopathy in which CD8+ T-lymphocytes attack non-necrotic muscle fibers, producing symmetrical proximal muscle weakness that develops over weeks to months. It is rare, affecting roughly 1-10 new patients per million adults per year, with peak onset between ages 40 and 60 and a female-to-male ratio near 2:1.
Polymyositis (ICD-10: M33.20-M33.29) is one of the idiopathic inflammatory myopathies, a family that also includes dermatomyositis, immune-mediated necrotizing myopathy, inclusion body myositis, and overlap syndromes. The pathogenic lesion is endomysial infiltration by CD8+ cytotoxic T-cells that surround and invade non-necrotic muscle fibers expressing aberrant major histocompatibility class I antigen, leading to fiber necrosis, regeneration, and progressive functional loss. Polymyositis is now defined more narrowly than in earlier decades: many patients previously labeled polymyositis are reclassified after biopsy as immune-mediated necrotizing myopathy or as part of an antisynthetase syndrome. The 2017 EULAR/ACR classification criteria provide a weighted score combining age at onset, pattern of weakness, skin findings, laboratory tests, and biopsy features.
key facts
Prevalence
1-10 cases per million adults per year (incidence); estimated prevalence 9-32 per 100,000 (Furst et al. 2012, US claims data)
Demographics
Female-to-male ratio approximately 2:1; higher prevalence in adults of African and Hispanic ancestry in US registries
Avg. age
Adult-onset typical between 40 and 60 years; juvenile polymyositis is exceptionally rare (juvenile dermatomyositis is the pediatric counterpart)
Global cases
Estimated 70,000-150,000 affected adults worldwide; widely under-diagnosed in low- and middle-income countries
Specialist
Rheumatology
§ 02
How you might notice it
The key symptoms of Polymyositis are: Symmetrical proximal muscle weakness developing over weeks to months, affecting hips and shoulders before distal muscles — difficulty climbing stairs, getting out of a chair, or lifting heavy objects., Difficulty raising the arms to brush hair, reach overhead shelves, or hold objects at arm's length., Falls or near-falls when getting out of low chairs or off the toilet., Neck flexor weakness causing inability to lift the head off a pillow when lying flat., Dysphagia for solids and then liquids in 30-50% of patients, with pharyngeal pooling and nasal regurgitation., Myalgia (mild aching of large muscles) in 25-50% — pain is usually less prominent than weakness., Fatigue that is out of proportion to recent activity and not relieved by rest..
01Symmetrical proximal muscle weakness developing over weeks to months, affecting hips and shoulders before distal muscles — difficulty climbing stairs, getting out of a chair, or lifting heavy objects.
02Difficulty raising the arms to brush hair, reach overhead shelves, or hold objects at arm's length.
03Falls or near-falls when getting out of low chairs or off the toilet.
04Neck flexor weakness causing inability to lift the head off a pillow when lying flat.
05Dysphagia for solids and then liquids in 30-50% of patients, with pharyngeal pooling and nasal regurgitation.
§ 03
How it’s diagnosed
diagnosis
Diagnosis combines clinical history, examination, muscle enzyme testing, electromyography, autoantibody panels, imaging, and muscle biopsy. The patient's history identifies the timeline (weeks to months) and distribution (proximal greater than distal, symmetrical) of weakness. Examination distinguishes true weakness from pain-limited effort and rates each muscle group on the Medical Research Council scale. Initial laboratory workup measures creatine kinase, aldolase, lactate dehydrogenase, and aminotransferases — elevations are common but not specific. A myositis-specific antibody panel (anti-Jo-1, anti-PL-7, anti-PL-12, anti-EJ, anti-OJ, anti-KS, anti-SRP, anti-HMG-CoA reductase, anti-Mi-2, anti-TIF1-gamma, anti-NXP-2, anti-MDA5) is increasingly performed at presentation because antibody profile guides prognosis and screening. Electromyography shows the classic triad of small polyphasic motor unit potentials, fibrillations, and positive sharp waves. MRI of thighs identifies edema and active inflammation, helps target biopsy, and tracks treatment response. Muscle biopsy remains the gold standard for distinguishing polymyositis from necrotizing myopathy, inclusion body myositis, and dystrophy; needle or open biopsy is performed on an MRI-positive site avoiding recent EMG punctures. Once polymyositis is confirmed, age-appropriate cancer screening (CT chest/abdomen/pelvis, mammography, colonoscopy, pelvic ultrasound, prostate-specific antigen) is offered. High-resolution chest CT and pulmonary function tests assess for interstitial lung disease.
Key tests
01
Creatine kinase, aldolase, AST, ALT, LDHDetects muscle enzyme leak; creatine kinase typically 5-50 times normal in active disease
02
Myositis-specific and myositis-associated autoantibody panelDefines clinical subset (antisynthetase, necrotizing, overlap) and guides screening for lung and cancer involvement
✓Methotrexate 15-25 mg weekly (oral or subcutaneous) with folic acid 5 mg weekly
✓Azathioprine 2-3 mg/kg daily
✓Mycophenolate mofetil 2-3 g daily
§ 05
Causes & risk factors
known causes
Autoreactive CD8+ T-cell attack on muscle fibers
The proximate mechanism: endomysial CD8+ T-lymphocytes recognize aberrantly expressed MHC class I on muscle fiber surfaces, releasing perforin and granzymes that cause fiber necrosis. Biopsy shows characteristic surrounding and invasion of non-necrotic fibers.
Genetic susceptibility
HLA-DRB1*03:01 and the ancestral 8.1 haplotype confer roughly 3-5 fold risk in European populations. HLA associations vary by autoantibody subtype, particularly anti-Jo-1 with DRB1*03:01.
Environmental and infectious triggers
Ultraviolet light exposure (geographic gradient), viral infection (Coxsackie B, HIV, hepatitis C, HTLV-1), and seasonal pollen exposure correlate with disease onset in epidemiologic studies. No single trigger has been confirmed as causative.
Drug-induced myositis
Statins, fibrates, anti-tumor necrosis factor agents, hydroxyurea, and immune checkpoint inhibitors (pembrolizumab, nivolumab) can precipitate inflammatory myopathy. Checkpoint-inhibitor myositis has emerged as a distinct entity with frequent myocarditis and high mortality.
Autoantibody-driven disease
Antisynthetase antibodies (anti-Jo-1, anti-PL-7, anti-PL-12, anti-EJ, anti-OJ, anti-KS), anti-SRP, and anti-Mi-2 each define clinical subsets with characteristic organ involvement, response to therapy, and prognosis.
risk factors
Age 40-60non-modifiable
Peak incidence in the fifth and sixth decades. Onset before age 18 is rare and usually represents juvenile dermatomyositis rather than polymyositis.
§ 06
Living with it
01Disclose statin and checkpoint-inhibitor exposure to clinicians evaluating new muscle weakness; early withdrawal of the offending drug shortens recovery.
02Attend age-appropriate cancer screening at diagnosis and annually for the first 3 years.
03Vaccinate against influenza, pneumococcus, herpes zoster, and SARS-CoV-2 before starting immunosuppression where possible.
04Maintain physical activity within tolerance during remission to slow muscle deconditioning.
05Adhere to prescribed taper schedules; abrupt steroid discontinuation is the most common cause of early relapse.
recommended foods
•Protein intake of 1.2-1.6 g/kg/day to support muscle rebuilding during recovery
•Calcium-rich foods (dairy, leafy greens, fortified plant milks) and vitamin D to offset steroid-induced bone loss
•Mediterranean-style diet emphasizing oily fish, vegetables, legumes, and olive oil
•Modified textures (mechanical soft, pureed, thickened liquids) where dysphagia is present, guided by a speech-language pathologist
§ 07
When to seek help
why see a rheumatology
Polymyositis is uncommon and frequently misdiagnosed; specialist rheumatology input is essential to confirm diagnosis, select autoantibody-appropriate therapy, and avoid the common pitfall of treating fibromyalgia or polymyalgia rheumatica with high-dose steroids. Pulmonology involvement is mandatory when interstitial lung disease is present, and gastroenterology and speech-language pathology when dysphagia is identified.
01Interstitial lung disease — develops in 20-40% over the disease course and is the leading cause of death; baseline and serial high-resolution CT plus pulmonary function tests are essential.
02Dysphagia and aspiration pneumonia from pharyngeal weakness — requires speech-language assessment and may need percutaneous gastrostomy in severe cases.
03Cardiac involvement including myocarditis, arrhythmias, and conduction disease — baseline ECG and echocardiogram at diagnosis; troponin monitoring when symptoms develop.
04Cancer association — polymyositis carries a 1.4-2 fold increased risk of malignancy in the first 3 years; full age-appropriate screening at diagnosis and on relapse.
05Steroid-induced osteoporosis and avascular necrosis — bone protection from day one, with bone-density scan within 3 months of starting prednisone.
Classical polymyositisAdult-onset symmetrical proximal muscle weakness without rash, elevated creatine kinase, endomysial CD8+ infiltrate on biopsy, and exclusion of other myopathies. Now considered uncommon as a pure entity; many cases meet criteria for overlap or necrotizing myopathy.
Antisynthetase syndromeDefined by autoantibodies against aminoacyl-tRNA synthetases (anti-Jo-1 most common). Features non-erosive arthritis, Raynaud's phenomenon, mechanic's hands, fever, and high rates of interstitial lung disease. Pulmonary involvement determines prognosis.
Overlap myositisPolymyositis features alongside systemic sclerosis, lupus, Sjogren syndrome, or rheumatoid arthritis. Diagnosis requires criteria for both conditions. Treatment often requires combination immunosuppression.
Cancer-associated myositisInflammatory myopathy diagnosed within three years of a malignancy. More common in dermatomyositis than polymyositis (relative risk 1.4-2.0 in polymyositis versus 3-5 in dermatomyositis). Triggers extensive cancer screening at diagnosis.
Statin-induced and necrotizing autoimmune myopathyAnti-HMG-CoA reductase antibody-mediated necrotizing myopathy can follow statin exposure; presents similarly to polymyositis but biopsy shows necrosis without endomysial inflammation. Increasingly recognized as a distinct entity requiring rapid steroid taper plus IVIG.
Living with Polymyositis
Timeline
Creatine kinase falls within 2-6 weeks of starting prednisone; objective strength gains lag by 4-12 weeks because muscle fiber regeneration takes longer than enzyme leak resolution. Most patients return to near-baseline function over 6-12 months. Steroid taper extends over 9-18 months. Annual flares occur in 30-40% of patients and typically respond to brief steroid pulses.
Lifestyle
01Take prednisone with food in the morning to align with circadian cortisol and minimize insomnia.
02Begin or continue supervised exercise within 2 weeks of starting treatment, including aerobic and resistance training tailored to current strength.
03Use modified utensils, raised toilet seats, and grab bars during initial weakness; many adaptations can be discontinued as strength returns.
04Sit upright for at least 30 minutes after meals if dysphagia is present, and use thickened liquids if recommended by speech-language pathology.
05Monitor blood glucose, blood pressure, and weight during steroid therapy; both diabetes and hypertension can emerge within weeks.
06Use sunscreen (especially in antisynthetase syndrome and overlap disease) to limit photo-aggravated skin changes.
Daily management
01Take medications at consistent times to maintain steady drug levels; methotrexate is taken once weekly on the same day.
Complementary approaches
Structured exercise therapySupervised aerobic and progressive resistance training improves muscle strength and aerobic capacity without raising creatine kinase. Recommended once induction reduces active inflammation; randomized trials show 15-25% gains in maximal voluntary contraction at 6 months.
Vitamin D and creatine supplementationVitamin D 800-2000 IU daily is recommended for steroid-induced bone protection. Creatine monohydrate 3-5 g daily has small but consistent benefits on strength in randomized trials of inflammatory myopathy.
Choosing a doctor
Choose a rheumatologist with myositis-clinic experience, access to a full myositis-specific autoantibody panel, and a multidisciplinary network including a neuromuscular pathologist, pulmonologist, and physical and occupational therapists trained in inflammatory myopathy. Tertiary myositis units publish outcome data and participate in trials.
Patient support resources
The Myositis Association →Global patient organization providing education, support groups, registry data, and clinician referrals.
Cure JM Foundation →Focused on juvenile myositis but provides relevant resources for adult patients and clinicians.
Myositis UK →UK-based patient charity offering helpline, local support groups, and research updates.
§ 08
Frequently asked
What is polymyositis in simple terms?▾▴
Polymyositis is a rare autoimmune disease in which the immune system attacks muscle fibers and causes symmetrical weakness in the hips, shoulders, and neck. It develops over weeks to months and is treated with steroids combined with steroid-sparing immunosuppressants.
What are the first signs of polymyositis?▾▴
The earliest sign is symmetrical proximal muscle weakness, usually difficulty rising from a chair, climbing stairs, or lifting objects overhead. Creatine kinase levels are often raised on routine blood tests. Skin rash, joint pain, and Raynaud's phenomenon may precede weakness in antisynthetase syndrome.
What is the difference between polymyositis and dermatomyositis?▾▴
Both cause symmetrical proximal weakness with raised creatine kinase. Dermatomyositis additionally produces characteristic skin changes including a heliotrope rash, Gottron's papules, and the shawl sign, and is more strongly linked to cancer. Polymyositis has no skin involvement.
How is polymyositis diagnosed?▾▴
Diagnosis combines muscle enzyme testing (raised creatine kinase), electromyography, MRI of muscles, muscle biopsy showing CD8+ T-cell infiltration, and myositis-specific autoantibody panels. Cancer screening is also performed because of the association between inflammatory myopathy and malignancy.
How is polymyositis treated?▾▴
First-line treatment is oral prednisone 1 mg/kg per day combined with a steroid-sparing immunosuppressant such as methotrexate or azathioprine. Mycophenolate mofetil, IVIG, and rituximab are added for refractory disease or lung involvement. Physiotherapy is started within 2 weeks of starting steroids.
Is polymyositis curable?▾▴
Polymyositis is rarely cured outright but is controllable in most patients. About 20% achieve sustained drug-free remission, 50-60% require long-term maintenance immunosuppression with intermittent flares, and 15-20% have refractory disease needing advanced therapies such as rituximab or IVIG.
What is the life expectancy for polymyositis?▾▴
With modern treatment, 5-year survival is 75-90% and 10-year survival is 70-80% in specialist cohorts. The main causes of reduced life expectancy are interstitial lung disease, associated cancer, infections from immunosuppression, and cardiac involvement.
Does polymyositis cause pain?▾▴
Mild muscle aching occurs in 25-50% of patients, but pain is usually less prominent than weakness. Severe pain raises the suspicion of necrotizing myopathy, rhabdomyolysis, or an alternative diagnosis such as polymyalgia rheumatica or fibromyalgia.
Is polymyositis hereditary?▾▴
Polymyositis is not inherited in a Mendelian pattern but susceptibility is influenced by HLA-DRB1*03:01 and other immune-related genes. First-degree relatives have a small absolute increase in risk for autoimmune disease in general but rarely develop polymyositis themselves.
Can polymyositis affect the lungs?▾▴
Yes. Interstitial lung disease develops in 20-40% of patients over the disease course, particularly in those with anti-Jo-1 or other antisynthetase antibodies. It is the leading cause of mortality. Screening with high-resolution chest CT and pulmonary function tests is performed at diagnosis.
Can polymyositis affect swallowing?▾▴
Dysphagia affects 30-50% of patients because the upper-pharyngeal muscles are striated and susceptible. Patients describe food sticking in the throat, nasal regurgitation, and aspiration during meals. Speech and swallowing therapy and modified diets are part of standard management.
Is polymyositis linked to cancer?▾▴
Polymyositis carries a 1.4-2 fold increased risk of malignancy within 3 years of diagnosis. Dermatomyositis carries a higher risk (3-5 fold). Age-appropriate cancer screening is performed at diagnosis and during the first 3 years; certain autoantibodies such as anti-TIF1-gamma identify higher-risk patients.
What is antisynthetase syndrome?▾▴
Antisynthetase syndrome is defined by autoantibodies against aminoacyl-tRNA synthetases (anti-Jo-1 most common) and features inflammatory myopathy, interstitial lung disease, non-erosive arthritis, mechanic's hands, Raynaud's phenomenon, and fever. Lung involvement determines prognosis.
Can statins cause polymyositis?▾▴
Statins can cause anti-HMG-CoA reductase necrotizing myopathy, which resembles polymyositis with raised creatine kinase and weakness but shows necrosis rather than inflammation on biopsy. Symptoms persist after stopping the statin and usually require steroids plus IVIG.
Does exercise help or worsen polymyositis?▾▴
Supervised aerobic and resistance exercise improves strength and aerobic capacity without raising creatine kinase or worsening inflammation. Trials show 15-25% gains in maximal voluntary contraction over 6 months. Exercise is started within 2 weeks of beginning immunosuppression.
What blood tests track polymyositis activity?▾▴
Creatine kinase, aldolase, AST, ALT, and LDH track muscle enzyme activity. Improvement typically appears within 2-6 weeks of starting prednisone. Inflammatory markers (CRP, ESR) and KL-6 follow lung involvement. Antibody titres are not reliable activity markers.
Can polymyositis come back after treatment?▾▴
Yes. Relapse occurs in 30-40% of patients annually, usually during steroid taper or after dose reduction of the steroid-sparing agent. Relapses typically respond to brief steroid pulses and increased immunosuppression. Long-term remission is more likely with combination therapy from the outset.
Is polymyositis common in children?▾▴
True polymyositis is rare in children. Most pediatric inflammatory myopathies are juvenile dermatomyositis, which has distinctive skin features and a different treatment approach. Reclassification of historical pediatric polymyositis as juvenile dermatomyositis or other myopathies is common.
How long do steroids last in polymyositis treatment?▾▴
Prednisone is started at 1 mg/kg daily and maintained for 4-8 weeks, then tapered over 9-12 months. Many patients remain on a low maintenance dose (5-10 mg daily) for 1-2 years. Steroid-sparing immunosuppressants are added to limit cumulative exposure and side effects.
Is IVIG effective in polymyositis?▾▴
Yes. The 2022 ProDERM trial showed Total Improvement Score response in 79% of patients treated with intravenous immunoglobulin versus 44% with placebo at 16 weeks. IVIG is now FDA- and EMA-approved for adult dermatomyositis and used in refractory polymyositis and dysphagia.
Can polymyositis affect the heart?▾▴
Cardiac involvement occurs in 10-30% of patients and includes myocarditis, conduction disease, arrhythmia, and rarely cardiomyopathy. Baseline ECG and echocardiogram are standard at diagnosis. Troponin monitoring is added when new chest pain, dyspnea, or palpitations develop.
ElectromyographyIdentifies myopathic motor unit potentials with spontaneous activity supporting inflammatory rather than neurogenic disease
04
MRI of thighs or symptomatic musclesDemonstrates active myositis (edema on STIR or T2 fat-saturation), guides biopsy, and quantifies fatty replacement in chronic disease
05
Muscle biopsy (needle or open)Gold-standard confirmation, distinguishes polymyositis from necrotizing myopathy, dystrophy, and inclusion body myositis
06
High-resolution chest CT and pulmonary function testsScreens for interstitial lung disease, the leading cause of mortality in antisynthetase syndrome
07
Age- and sex-appropriate cancer screeningIdentifies occult malignancy at diagnosis and during the first 3 years of follow-up
Outlook
With current immunosuppression, 5-year survival in adult polymyositis is 75-90% and 10-year survival around 70-80%, a substantial improvement over the 50-60% 5-year survival of the 1970s. Prognosis is dominated by extra-muscular features: interstitial lung disease (especially when anti-MDA5 or anti-Jo-1 positive), associated malignancy, cardiac involvement, and severe dysphagia carry the greatest risk. About 20% of patients achieve sustained drug-free remission, 50-60% require maintenance immunosuppression with intermittent flares, and 15-20% have refractory disease requiring rituximab, IVIG, or trial therapies. Functional outcomes are favorable when treatment starts within 6 months of symptom onset; delay beyond 12 months correlates with permanent muscle atrophy and dependence. Cancer-associated myositis has the poorest survival, dominated by the underlying tumor; antisynthetase syndrome with rapidly progressive lung disease and anti-MDA5 dermatomyositis variants have 6-month mortality up to 50%.
Female sexnon-modifiable
Female-to-male ratio approximately 2:1 in adult cohorts; the gap narrows in cancer-associated and overlap forms.
African and Hispanic ancestry (US registries)genetic
Adjusted prevalence is 1.5-2 times higher than in non-Hispanic white populations, partly reflecting HLA distribution. Disease severity and renal involvement also tend to be higher.
HLA-DRB1*03:01 carriagegenetic
Strongest genetic association in European populations; risk ratio 3-5. Influences autoantibody profile and likelihood of interstitial lung disease.
Statin and immune-checkpoint inhibitor exposuremodifiable
Statins are linked to anti-HMG-CoA reductase necrotizing myopathy; checkpoint inhibitors precipitate severe myositis in roughly 1% of treated patients with notable myocarditis risk.
Recent viral infectionenvironmental
Coxsackie B, HIV, hepatitis C, and HTLV-1 are associated with secondary inflammatory myopathy. Pandemic-era SARS-CoV-2 has been reported as a trigger in case series.
Coexisting autoimmune diseasenon-modifiable
Patients with systemic sclerosis, lupus, or Sjogren syndrome have elevated polymyositis risk through shared pathways and treatments.
foods to avoid
•Excess sodium (over 2.3 g/day) while on prednisone — accelerates hypertension and fluid retention
02Neuromuscular pathology with experience interpreting muscle biopsies
03Access to myositis-specific and -associated autoantibody panels
04Pulmonary function testing and high-resolution chest CT capability
05Physical and occupational therapy services with myositis-specific protocols
Essential facilities
Tertiary rheumatology and neuromuscular centersInterstitial lung disease clinicsSpeech and swallowing therapy servicesBone health and metabolic clinics for steroid-treated patientsClinical trial centers participating in myositis studies
02Record daily activities that are difficult (stairs, rising from chair, lifting) — a useful early indicator of relapse.
03Perform a 30-second sit-to-stand test once a month at home to track strength.
04Inspect skin daily during antisynthetase syndrome for new rash, mechanic's hands changes, or ulceration.
05Maintain hydration to support kidney function on immunosuppression.
06Attend follow-up rheumatology, pulmonology, and physiotherapy appointments on the schedule agreed at diagnosis.
Exercise
Begin gentle aerobic activity (stationary cycling, walking, water-based exercise) within 2 weeks of treatment, progressing to supervised resistance training as inflammation falls. Trials show resistance training does not raise creatine kinase or worsen disease and produces 15-25% strength gains over 6 months. Avoid exercise to exhaustion during active flares.